Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:
“KEYNOTE905:
Pembrolizumab + Enfortumab Vedotin before and after cystectomy improved EFS, OS and pCR vs surgery alone.
A new SOC may be on the horizon for this high-risk group. Can’t wait to see the full data!”
Petros Grivas, Clinical Director of the GU cancers Program at the University of Washington, shared a post by Yüksel Ürün, adding:
“Agree with Yüksel Ürün this is expected to be paradigm shifting in this population!
Can’t wait to see data! A few questions to ask preemptively:
- % of patients who received adjuvant Nivo in control group
- % histology subtype component
- Subsequent therapies in mUC
- Follow up duration”
More posts featuring Yüksel Ürün on OncoDaily.